Our CRO services in chronic kidney disease (CKD)

Accelerate your drug development by exploring clinical endpoints in our
rodent models of chronic kidney disease (CKD).

ReninAAV UNx db/db model

  • Hypertensive, type 2 diabetic mouse model of diabetic kidney disease
  • Adeno-associated virus-induced hypertension in uninephrectomized db/db mice
  • Progressive albuminuria and loss of kidney function
  • AI-assisted glomerulosclerosis scoring

5/6 nephrectomy model of CKD

  • Subtotal nephrectomy rat model of chronic kidney disease
  • Surgical reduction of nephron mass for progressive kidney failure
  • Pronounced albuminuria and progressive loss of kidney function
  • Quantification and scoring of tubulointerstitial fibrosis and glomerulosclerosis

UUO model of kidney fibrosis

  • Unilateral ureteral obstruction mouse model
  • Permanent surgical obstruction for induction of kidney fibrosis and inflammation
  • 7-day study period optimal for drug screening and dose-range-finding

An introduction to rodent models of diabetic kidney disease

Reproducibility of the results from preclinical studies to clinical trials is critical for drug development. Gubra scientists have reviewed the translatability and predictability of the most widely used mouse and rat models of diabetic kidney disease (DKD). The conclusion is clear: Preclinical pharmacology studies using advanced models of DKD, such as Gubra’s ReninAAV UNx db/db mouse model, have better translatability.

Look at the kidney in a new perspective

Quantification of kidney histomorphometric endpoints is time consuming and costly. At Gubra, we have automized our 3D imaging analyses after light sheet microscopy to quantify structural endpoints such as the number and volume of glomeruli in the intact mouse kidney.

Download paper: Whole-kidney 3D imaging in a mouse model of diabetic kidney disease (25 Jun 2020)

Play video: Diabetic nephropathy (opens in new tab)

Gubra Kidney in vivo study approach

We offer rodent models of advanced diabetic kidney disease and chronic kidney disease.

We apply a sophisticated surgical techniques and induction of hypertension to accelerate kidney disease progression.

Clinical and preclinical endpoints are applied to improve model translatability.

 

Related Links:

Main offerings

 

  • Kidney function assessment by transdermal GFR measurement
  • Biochemical assessment of plasma and urine markers of kidney function and injury
  • AI-assisted scoring of glomerulosclerosis
  • Histomorphometric quantification of tubulointerstitial fibrosis and inflammation
  • RNA sequencing and bioinformatics of bulk RNA as well as isolated glomeruli and tubulointerstitium
  • 3D kidney imaging and automated analyses of structural and functional kidney endpoints

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Mette Viberg Østergaard

Senior Scientist

mvo@gubra.dk
+45 51226575